Your company just closed a financing, or dosed the first patient in a trial, or hired a chief medical officer from a big pharma company. Someone on the team says, “Let’s get it on BioSpace.” Ten minutes later, you are looking at an upload form and a $75 fee, and it seems the job is almost done.

It is not. Paying that fee gets your press release reviewed and, if approved, posted in BioSpace’s press release section. It does not get a BioSpace reporter to write about you. Those are two different doors, and most companies only know about one of them. This guide explains how to get featured on BioSpace through both, when each makes sense and how to write the editorial pitch that turns an announcement into a story.

Two doors into BioSpace

Purple solutions in a row of test tubes during an experiment, the science behind most BioSpace news

BioSpace has been around longer than most of its readers’ companies. It was founded in 1985 by Jennifer King as a directory of biotech organizations in what would become the Bay Area biotech cluster, and it launched its website in 1995 at an event for 300 biotech executives in Boston. Today it describes itself as a hub for life science news and jobs. In a March 2025 release marking its 30th anniversary, BioSpace reported more than one million monthly visitors and more than 405,000 email subscribers.

That mix of news and careers explains its two doors.

The first door is the paid press release. BioSpace’s editorial page says companies can submit a release for publication on the site for a nonrefundable fee of $75. The team reviews it, and releases relevant to a life sciences audience are approved and posted. Not every release is approved. When one is, it appears as a press release, in the company’s own words.

The second door is editorial coverage. BioSpace’s news team writes its own stories on clinical results, regulatory decisions, deals, layoffs, policy and the business of biopharma. Its editorial policy states that topics covered in news articles are chosen by the editorial team independent of client input. You cannot buy your way into this section. You have to pitch.

We call this the Two-Door Rule: decide which door you are knocking on before you write a word. A paid release is a record. An editorial story is a judgment by a journalist that your news matters to the industry. The second is worth far more, and it takes a different kind of preparation.

What BioSpace editors cover

BioSpace’s audience is people who work in the life sciences: scientists, clinicians, business development teams, executives, investors and job seekers watching which companies are growing or cutting. Its news coverage follows what that audience needs to know to make decisions about their work and careers.

That points to a few reliable story types. Clinical and regulatory news is the core: trial readouts, FDA decisions, advisory committee votes, clinical holds and approvals. Deals and financings come next, in particular when they are large, unusual or signal a shift in where money is going. Corporate changes, including restructurings, layoffs, site closures and leadership moves, get regular attention because the readers care about where the jobs are. Policy coverage has grown, including drug pricing, trade and the competitive race with China in biotech.

Look at a week of BioSpace’s front page and you will see the pattern. The stories with staff bylines are about consequence. They explain what a decision means for a company, a drug class or the people who work in the field. If your news does not change something for someone beyond your own company, it belongs behind the first door, not the second.

The careers angle is a quiet advantage. Because BioSpace serves job seekers, news that affects hiring has more weight here than at some trade outlets. A company opening a new manufacturing site with 200 jobs, or a startup building out a team in a region that is not a traditional hub, has a natural fit. Mention the hiring impact in your pitch when it is real.

Write the pitch the managing editor asked for

Person writing in a notebook beside a glass on a desk, drafting a short pitch before sending it

BioSpace does something many outlets do not: it tells you how it wants to be pitched. Its editorial page directs breaking news announcements to the managing editor by email and lists that address on the page. For feature ideas, it asks for details about the story focus, why it is timely now and the context or background of related activity in the space. It also says the team typically responds within 24 hours to pitches it is interested in.

Treat that guidance as a template. It gives you a three-line test that any pitch to BioSpace should pass before it goes out.

Line one is the focus. In one sentence, what is the story? Not “Company X announces Phase 2 results,” but “Company X’s Phase 2 data in 120 patients suggests its oral drug could match injectables on blood sugar control.” The second version tells an editor what they would be writing.

Line two is the timing. Why does this matter this week? Maybe a competitor reported data last month, a regulatory decision is due, or a funding environment has shifted. If you cannot say why now, the editor will not see a reason to run it now.

Line three is the context. What else is happening in this space that makes your news part of a bigger picture? Name the rival programs, the earlier failures, the policy change or the market trend. This is the line most companies skip, and it is the one that makes your news easier to write about.

Put those three lines at the top of the email. Follow with the key numbers, a link to the release or data, and a named executive available for interview with a time window. Keep the whole note under 200 words. Send it as close to the news as possible, and send it to the right person rather than every address you can find.

If the news is under embargo, say so in the subject line and state the embargo time. Do not send embargoed material to someone who has not agreed to it.

Opinion pieces and the career angle

Not every company has breaking news, but most have people who know things. BioSpace accepts contributed opinion pieces from industry experts. Its guidance asks that these present a strong, supported position on an event or ongoing trend in biopharma, stay nonpromotional and run under 1,000 words. Opinion pitches go to the managing editor as well.

This is one of the most practical paths for service providers, consultants and executives at companies without a big announcement. A CDMO executive arguing why onshoring timelines are slower than policy makers expect, or a clinical operations leader explaining why decentralized trial tools stalled after the pandemic, can make a useful piece if the argument is specific and backed by experience.

The test for an opinion pitch is simple: would the piece still be worth reading if your company’s name were removed? If the answer is no, it is promotional, and it will not run. If the answer is yes, your byline becomes the credibility.

The careers side of BioSpace also opens doors that pure news outlets do not. Executives with real views on hiring, workforce shifts, layoffs, compensation trends or skills gaps in biotech can be useful sources for career-related coverage. If your company has data on hiring in its region or specialty, that can be the start of a story.

Mistakes that sink BioSpace pitches

The first mistake is pitching the release itself. Forwarding your press release with “thought this might interest you” on top asks the editor to do the work of finding the story. Most will not. The three-line test exists so that you do that work first.

The second mistake is the vague result. Life sciences editors read data for a living. “Positive topline results” without the endpoint, the patient count and the effect size tells them you are hiding something, even when you are not. Lead with the number, then explain what it means.

The third mistake is ignoring what BioSpace already wrote. If the site covered your competitor’s trial in the same indication last month, your pitch should mention it and explain how your news adds to or challenges that story. Editors notice when a pitch shows it was written for their publication rather than copied to fifty.

The fourth mistake is confusing the doors. Some companies pay for a release and then email the editor asking why no reporter wrote about it. Others pitch the editor with a release that is mostly about a new logo. Both waste goodwill. Anyone serious about how to get featured on BioSpace should keep the two routes separate in their head and in their outreach plan.

The fifth mistake is the slow reply. If an editor answers your pitch, respond within the hour if you can, with the executive’s availability and any data they asked for. A story that needs a quote by 3 p.m. will run with someone else’s quote if yours arrives at 5.

When the $75 release is the right call

None of this means the paid release is a waste of money. It is just a different product. Posting a release on BioSpace puts your announcement on a site that a large life sciences audience reads, gives you a permanent, searchable record and can feed the other places your news travels. Search engines and AI assistants pick up announcements from trusted industry sites, so a release on BioSpace can help shape how your company is described later.

Use the paid route for news that matters to your stakeholders but is unlikely to earn a staff story on its own: a board appointment, a mid-size partnership, a conference presentation, a new site opening, a smaller financing. Write it well, include the numbers and make sure the first paragraph says what happened in plain words. A release that reads like a news story is more useful to readers and more likely to be approved.

Use the editorial route for news with consequence beyond your company. Then use both. Many companies post the release and pitch the editor at the same time. The release gives the reporter something to link to, and the pitch gives them a reason to write.

If you are building a target list across life sciences outlets, our free journalist list is a good place to start. For BioSpace, though, the most important research is free: read the editorial page, read a week of stories and pitch the way the editors have told you they want to be pitched. That is the core of how to get featured on BioSpace, and it is more than most companies do.